Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Multiple Sclerosis and Related Disorders
|
April 22, 2018
Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week
Patricia K Coyle, Shulian Shang, Zhen Xiao, et al.
Therapeutic Advances in Neurological Disorders
|
September 6, 2018
Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis
Douglas L Arnold, Shulian Shang, Qunming Dong, et al.
British Journal of Clinical Pharmacology
|
April 11, 2016
COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects
Xiao Hu, Shulian Shang, Ivan Nestorov, et al.
Computational Statistics & Data Analysis
|
January 26, 2016
Partially Linear Single Index Cox Regression Model in Nested Case-Control Studies
Shulian Shang, Mengling Liu, Anne Zeleniuch-Jacquotte, et al.
Journal of Neurology
|
June 18, 2016
Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis
Scott D Newsome, Bernd C Kieseier, Douglas L Arnold, et al.
Plos One
|
October 3, 2012
Application of the asthma phenotype algorithm from the Severe Asthma Research Program to an urban population
Paru Patrawalla, Angeliki Kazeros, Linda Rogers, et al.
Genome Research
|
June 11, 2011
Quantitative evaluation of all hexamers as exonic splicing elements
Shengdong Ke, Shulian Shang, Sergey M Kalachikov, et al.
Frontiers in Neurology
|
April 28, 2023
A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder
Achim Berthele, Michael Levy, Dean M Wingerchuk, et al.
Therapeutic Advances in Neurological Disorders
|
September 6, 2018
Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN
Scott D Newsome, Thomas F Scott, Douglas L Arnold, et al.
Plos One
|
October 8, 2011
The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma
Chanh Huynh, Laura Poliseno, Miguel F Segura, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Multiple Sclerosis and Related Disorders
|
April 22, 2018
Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week
Patricia K Coyle, Shulian Shang, Zhen Xiao, et al.
Therapeutic Advances in Neurological Disorders
|
September 6, 2018
Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis
Douglas L Arnold, Shulian Shang, Qunming Dong, et al.
British Journal of Clinical Pharmacology
|
April 11, 2016
COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects
Xiao Hu, Shulian Shang, Ivan Nestorov, et al.
Computational Statistics & Data Analysis
|
January 26, 2016
Partially Linear Single Index Cox Regression Model in Nested Case-Control Studies
Shulian Shang, Mengling Liu, Anne Zeleniuch-Jacquotte, et al.
Journal of Neurology
|
June 18, 2016
Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis
Scott D Newsome, Bernd C Kieseier, Douglas L Arnold, et al.
Plos One
|
October 3, 2012
Application of the asthma phenotype algorithm from the Severe Asthma Research Program to an urban population
Paru Patrawalla, Angeliki Kazeros, Linda Rogers, et al.
Genome Research
|
June 11, 2011
Quantitative evaluation of all hexamers as exonic splicing elements
Shengdong Ke, Shulian Shang, Sergey M Kalachikov, et al.
Frontiers in Neurology
|
April 28, 2023
A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder
Achim Berthele, Michael Levy, Dean M Wingerchuk, et al.
Therapeutic Advances in Neurological Disorders
|
September 6, 2018
Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN
Scott D Newsome, Thomas F Scott, Douglas L Arnold, et al.
Plos One
|
October 8, 2011
The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma
Chanh Huynh, Laura Poliseno, Miguel F Segura, et al.
Page
of 2